Gsk Share Discussion Threads

[pugugly] 02/6/2024 14:30

PJ84 - Many thanks for extract - May GSK continue to Fight the Good fight.

[pj84] 02/6/2024 14:14

Also from the article:-

"The company said it disagrees with the ruling and will be seeking an appeal.

A spokesperson said: “GSK will continue to vigorously defend itself against all claims and manage this litigation in the best interests of shareholders. Alongside immediately seeking an appeal to the Delaware State Court, the company will file motions for dismissal pressing additional defences, severance of cases and proof-of-use by claimants; and, at the same time, the company will progress to trials of individual cases.”

One company insider added: “The science and facts are on our side and we are going to fight this all the way through the courts. This is procedural, not a verdict, and does nothing to impact our growth plans.”"

and

"The first Zantac jury trial took place last month, with lawyers representing 89-year-old Angela Valadez arguing that the drug had played a part in her developing colon cancer. However, the jury found in GSK’s favour."

[pugugly] 02/6/2024 10:09

From Sunday Times
"Business

Blow to GSK in Zantac saga as Delaware court gives green light to 72,000 lawsuits
GSK has suffered a big setback in the legal battle over its discontinued heartburn medication Zantac, after a judge in the US waved through lawsuits brought by 72,000 people who claim it gave them cancer. Delaware State Court ruled late on Friday that plaintiffs were allowed to bring forward their expert witnesses in trials against GSK.

[rikky72] 01/6/2024 16:54

'Juries are the ultimate fact finders'. Really? When at least half the US population are pig sh*t ignorant? What a load of embarrassing nonsense. Hopefully this gets overturned on appeal.

[geckotheglorious] 01/6/2024 16:37

"GSK, Pfizer must face tens of thousands of Zantac cases in Delaware"

A Delaware state court judge late Friday ruled that about 75,000 lawsuits against GSK (NYSE:GSK) and Pfizer (NYSE:PFE) over claims Zantac causes cancer can move forward as evidence brought by plaintiffs is legitimate.

In her ruling, Superior Court Judge Vivian Medinilla wrote that juries are "the ultimate fact finders" and it would be inappropriate for a court to get in the middle of a debate over science.

"This dispute presents a classic battle of the experts," she wrote.
Plaintiffs are claiming that ranitidine, the active ingredient in Zantac, could eventually contain the carcinogen NDMA. An FDA recall ordered Zantac from the market in 2020.

Medinilla cited that recall in allowing experts to testify that NDMA can cause cancer and ranitidine can change and contain NDMA, Bloomberg reported.

GSK said it will seek an appeal of the ruling. The British pharma added there is no "reliable evidence" ranitidine increases the risk of any type of cancer. They added that the ruling is inconsistent with the Federal Court's Multidistrict Litigation ruling, which dismissed cases in December 2022.

[dplewis1] 30/5/2024 15:45

GS initiates coverage with neutral rating 1850p price target

[igoe104] 24/5/2024 08:19

Traders have been spooked by the general election announcement and are cashing in, seems to be the situation with most large caps at the moment..

These traders are a very nervy bunch, all it takes for the king to break a nail and they go all cash again, must be constantly in and out the market...

[drk1] 24/5/2024 08:15

Thought that news would give the share price a nice little boost - let's see how they react over the pond later on. ;-)

[panache1] 24/5/2024 07:07

Issued: 23 May 2024, London UK Statement: Zantac (ranitidine) litigation - Valadez and Williams cases · Jury in Valadez case in Illinois state court finds GSK not liable for plaintiff's colorectal cancer· Verdict is consistent with scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer· GSK will continue to vigorously defend itself against all other claims· Next Zantac trial (Williams) due to start in Illinois dismissed GSK plc (LSE/NYSE: GSK) welcomes today's jury verdict in the Valadez case in Illinois state court finding in GSK's favour in the first Zantac case to go to trial. This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims. Prior to this verdict, the court rejected the Plaintiff's ability to request punitive damages. Separately, the company welcomed the recent court ruling dismissing the next Zantac trial (Williams) that was due to start on 23 May 2024. In the Williams case, the Illinois state court dismissed the case before trial on the basis that GSK was not the brand manufacturer of over-the-counter Zantac at the time the Plaintiff allegedly used it and should not be liable for any subsequent over-the-counter Zantac use. ?

[dplewis1] 24/5/2024 07:07

Verdict is consistent with scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer

[lippy4] 22/5/2024 16:45

its typical american plundering by lawsuit with out any real evidence as every body jumps on the money wagon..

[zho] 22/5/2024 16:06

GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays.

Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen. This discovery led to numerous lawsuits from patients who alleged that they developed cancer after using the drug.

The potential figure for GSK is informed by recent settlements by other pharmaceutical companies, notably Pfizer.

According to the Financial Times, Pfizer recently settled more than 10,000 US Zantac cases for up to $250 million, which sets a benchmark of approximately $25,000 per case. This figure has influenced Barclays' estimate of GSK's potential settlement costs.

[abdullla] 22/5/2024 16:03

More majic

[tradermichael] 22/5/2024 09:07

16 pounds is 150p away from 1750p. So is 19 pounds ..... ;0)

[abdullla] 22/5/2024 08:09

Not far from the good old 16 pounds

[tradermichael] 21/5/2024 15:46

In a statement, GSK said it will defend against Valisure's meritless lawsuit, and that the FDA has found the lab's tests "scientifically flawed and unreliable."
GSK also said there remains no consistent or reliable evidence that ranitidine increases cancer risks.

[pcok] 21/5/2024 13:36

Don't have a Bloomberg subscription. Can you summarise or suggest a different link if possible. TIA.

[zho] 21/5/2024 10:25

GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay

The story of Emma Walmsley’s turnaround of the British drugmaker

[tradermichael] 21/5/2024 10:07

Well, a therapy for Asthma has taken that long - the drug is part of a range of 'new technology' advances (Monoclonal antibodies (MABs) are a type of targeted drug therapy.)

[alphorn] 21/5/2024 09:43

An experimental drug (which has taken 60 years of research), depemokimab............
So how strong is the patent?

[tradermichael] 21/5/2024 09:34

This morning GSK announced some big pipeline news. An experimental drug (which has taken 60 years of research), depemokimab, reduced asthma attacks in late-stage trials. The results pave the way for a treatment the company thinks could exceed £3 billion in sales.

[rikky72] 21/5/2024 09:11

Sad how many vultures and scam artists a company of GSK's size attracts.. hopefully this whole episode can be put to bed soon!